Catalyst Pharmaceutical: A Top Value Stock for Long-Term Investors

Catalyst Pharmaceutical (CPRX) is a top value stock for the long-term, according to Zacks Investment Research. With a Zacks Rank #2 (Buy) and a Value Style Score of A, CPRX is trading at a forward P/E of 9.6X, compared to the Medical - Drugs industry's P/E of 13.1X. The company has a PEG Ratio of 0.8, a Price/Cash Flow ratio of 8.8X, and a Price/Sales ratio of 4.9X. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025, with an average earnings surprise of 28.2%. CPRX is a strong value and VGM stock with impressive earnings and valuation fundamentals.